BioLight Life Sciences Ltd. (TLV:BOLT)
Israel
· Delayed Price · Currency is ILS · Price in ILA 235.50
-5.60 (-2.32%)
Apr 28, 2026, 5:24 PM IDT
BioLight Life Sciences Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | - | 0.22 | 0.12 | 0.06 | 0 | Upgrade
|
| Revenue Growth (YoY) | - | 85.59% | 87.30% | 2000.00% | -90.32% | Upgrade
|
| Gross Profit | - | 0.22 | 0.12 | 0.06 | 0 | Upgrade
|
| Selling, General & Admin | 10.15 | 6.66 | 6.25 | 6.86 | 6.27 | Upgrade
|
| Research & Development | 5.06 | 3.67 | 4.52 | 3.53 | 4.34 | Upgrade
|
| Operating Expenses | 15.21 | 10.34 | 10.77 | 10.39 | 10.61 | Upgrade
|
| Operating Income | -15.21 | -10.12 | -10.65 | -10.32 | -10.6 | Upgrade
|
| Interest Expense | -0.08 | -0.08 | -0.08 | -0.07 | -0.02 | Upgrade
|
| Interest & Investment Income | 0.18 | 0.06 | 0.26 | 0.01 | 0.07 | Upgrade
|
| Earnings From Equity Investments | -0.46 | -0.29 | -0.39 | -0.63 | -0.28 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.23 | -0.31 | 0.04 | 0.57 | -0.88 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.14 | -0.17 | -0.96 | 0.3 | -0.27 | Upgrade
|
| EBT Excluding Unusual Items | -15.66 | -10.92 | -11.77 | -10.14 | -11.98 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.25 | 2.49 | -15.72 | 1.45 | 10.07 | Upgrade
|
| Pretax Income | -16.91 | -8.42 | -27.49 | -8.69 | -1.91 | Upgrade
|
| Income Tax Expense | - | - | - | - | -1.57 | Upgrade
|
| Earnings From Continuing Operations | -16.91 | -8.42 | -27.49 | -8.69 | -0.34 | Upgrade
|
| Net Income to Company | -16.91 | -8.42 | -27.49 | -8.69 | -0.34 | Upgrade
|
| Minority Interest in Earnings | 5.18 | 1.28 | 1.47 | 0.84 | 0.72 | Upgrade
|
| Net Income | -11.73 | -7.14 | -26.02 | -7.85 | 0.38 | Upgrade
|
| Net Income to Common | -11.73 | -7.14 | -26.02 | -7.85 | 0.38 | Upgrade
|
| Shares Outstanding (Basic) | 6 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 6 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 27.27% | 0.29% | 1.70% | -0.41% | 0.94% | Upgrade
|
| EPS (Basic) | -1.98 | -1.53 | -5.60 | -1.72 | 0.08 | Upgrade
|
| EPS (Diluted) | -1.98 | -1.53 | -5.60 | -1.72 | 0.08 | Upgrade
|
| Free Cash Flow | -10.86 | -11.02 | -10.99 | -9.57 | -10.63 | Upgrade
|
| Free Cash Flow Per Share | -1.83 | -2.37 | -2.37 | -2.10 | -2.32 | Upgrade
|
| Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | -4619.64% | -9026.27% | -16384.13% | -353433.33% | Upgrade
|
| Profit Margin | - | -3261.19% | -22050.85% | -12455.56% | 12733.33% | Upgrade
|
| Free Cash Flow Margin | - | -5032.88% | -9315.25% | -15193.65% | -354333.33% | Upgrade
|
| EBITDA | -15.17 | -10.06 | -10.08 | -9.73 | -10.07 | Upgrade
|
| D&A For EBITDA | 0.03 | 0.06 | 0.57 | 0.59 | 0.53 | Upgrade
|
| EBIT | -15.21 | -10.12 | -10.65 | -10.32 | -10.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.